Why sun pharma share is going down?

As of late 2023/early 2024, Sun Pharma's stock has faced pressure due to a few key reasons. This is not financial advice, please consult a SEBI-registered advisor.

• USFDA Observations: The company received some observations (Form 483) from the US Food and Drug Administration at its Mohali plant. While not the strictest warning, any FDA scrutiny creates uncertainty and worries investors about potential future regulatory hurdles or delays in drug approvals from that facility.
• Whistleblower Allegations: There were renewed concerns stemming from an old whistleblower case related to certain distributions, creating negative sentiment.
• Broader Market and Sectoral Weakness: The entire pharmaceutical sector, especially Indian pharma, has been facing headwinds like pricing pressure in the US market.

For the most current analysis, check out financial news sites like Moneycontrol or Economic Times for their latest updates on the stock.